Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Verapamil SR in Adults With Type 1 Diabetes (Ver-A-T1D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04545151
Recruitment Status : Not yet recruiting
First Posted : September 10, 2020
Last Update Posted : September 10, 2020
Sponsor:
Collaborator:
Juvenile Diabetes Research Foundation
Information provided by (Responsible Party):
Medical University of Graz

Brief Summary:

This study has been set up within the framework of the INNODIA network. INNODIA is a global partnership between 27 academic institutions, 4 industrial partners, a small sized enterprise and 2 patient organisations, bringing their knowledge and experience together with one common goal: "To fight type 1 diabetes". (www.innodia.eu) The overall aim of INNODIA is to advance in a decisive way how to predict, stage, evaluate and prevent the onset and progression of type 1 diabetes (T1D).

For this, INNODIA has established a comprehensive and interdisciplinary network of clinical and basic scientists, who are leading experts in the field of T1D research in Europe and UK (United Kingdom), with complementary expertise from the areas of immunology, Beta-cell biology, biomarker research and T1D therapy, joining forces in a coordinated fashion with industry partners and two foundations, as well as with all major stakeholders in the process, including regulatory bodies and patients with T1D and their families.


Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Drug: Verapamil SR Drug: Placebo Phase 2

Detailed Description:

The study is a multicenter, randomized, double-blind, placebo-controlled study in volunteers with newly diagnosed diabetes mellitus type 1 (within 6 weeks after diagnosis).

The purpose of the clinical trial is to confirm the effect of 360mg Verapamil sustained release (SR) administered orally once daily (titrated over the first 3 months from 120 mg to 360 mg) on the preservation of beta-cell function measured as stimulated C-peptide after 12 months compared to placebo.

The study has a cross-over design and a duration of approximately 24 months, consisting of 3 telephone visits and 7 visits at the trial site. The duration of the treatment phase with verapamil is 12 months, and an additional (optional) follow-up visit will be carried out 12 months after completion of the study. The study procedures are identical in all 20 clinical centres across Europe and the UK.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 138 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Trial participants and research teams will be blinded to the treatment group for the duration of the trial. The double blinding will be achieved by providing verapamil SR identical placebo tablets.
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
Estimated Study Start Date : November 2020
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Verapamil SR
Eligible participants will be randomised into the verapamil SR arm and receive instructions on frequency of administration (daily intake). 80 participants on the experimental arm are expected to complete the trial.
Drug: Verapamil SR

Study drug will be provided in blisters and packaged and labelled. Each package will be labeled as required per country requirement. Labels will be blinded.

Drug adminstration:

  • from Day 0 to Week 4: 120 mg once daily
  • from Week 4 to Week 8: 240 mg once daily
  • from Week 8 to Month 12: 360 mg once daily
Other Name: Isoptin retard 120 mg

Placebo Comparator: Placebo

Eligible participants will be randomised into the Placebo arm and receive instructions on frequency of administration (daily intake).

40 participants on the control arm are expected to complete the trial.

Drug: Placebo

Placebo will be provided in blisters and packaged and labelled. Each package will be labeled as required per country requirement. Labels will be blinded.

Drug adminstration:

  • from Day 0 to Week 4: 120 mg once daily
  • from Week 4 to Week 8: 240 mg once daily
  • from Week 8 to Month 12: 360 mg once daily
Other Name: Matching Placebo for Verapamil SR




Primary Outcome Measures :
  1. Area under the stimulated C-peptide response curve [ Time Frame: At 12 months ]
    The primary objective is to determine the changes in stimulated C-peptide response during the first two hours of a mixed meal tolerance test (MMTT) at baseline and after 12 months for 360mg Verapamil SR administered orally once daily versus placebo.


Secondary Outcome Measures :
  1. Area under the stimulated C-peptide response curve [ Time Frame: At 3, 6, 9 and 24 months ]
    The area under the stimulated C-peptide response curve over the first two hours of a mixed meal tolerance test (MMTT)

  2. Proinsulin and preproinsulin secretion [ Time Frame: At baseline and 3, 6, 9 and 12 months ]
    Proinsulin and preproinsulin secretion during the first two hours of a mixed meal tolerance test (MMTT)

  3. Fasting C-peptide [ Time Frame: At 12 months ]
    To determine the effects of 360mg Verapamil SR administered orally once daily on fasting C-peptide and Dried Blood Spot (DBS) C-peptide measurements over time.

  4. DBS C-peptide [ Time Frame: At baseline, week 4, week 8, and 3, 6, and 9 months ]
    The DBS (Dried blood spot) C-peptide measurements at all observation times

  5. Change in HbA1c [ Time Frame: Baseline, 12 and 24 months ]
    To determine the effects of 360mg Verapamil SR administered orally once daily on HbA1c daily total insulin dose and continous glucose monitoring (CGM) time in range.

  6. Severe hypoglycaemic episodes [ Time Frame: Baseline to 12 months ]
    Number of treatment emergent severe hypoglycaemic episodes. Severe hypoglycaemia denotes severe cognitive impairment requiring external assistance for recovery according to the American Diabetes Association (ADA)

  7. DKA [ Time Frame: Baseline to 12 months ]
    Number of treatment emergent episodes of diabetic ketoacidosis

  8. Change in insulin requirements [ Time Frame: Baseline, 12 and 24 months ]
    Change in insulin requirements, baseline to 12 months as the daily total dose (three days average) in units per kg body weight (BW)

  9. Change in T1D associated autoantibodies [ Time Frame: Baseline to 12 months ]
    Change in T1D associated autoantibodies (GADA, IAA, IA-2A and ZnT8A) from baseline to 12 months

  10. Continous glucose monitoring (CGM) [ Time Frame: At Baseline and every 2 weeks prior to each visit (week 4, week 8, and 3, 6, and 9 months) ]
    Continous glucose monitoring (CGM) time in range (70-140 mg/dL, 3.9-7.8 mmol/L) and (70-180 mg/dL, 3.9-10.0 mmol/L), time above range (>180 mg/dL, >10.0 mmol/L), time below range (<70 mg/dL, < 3.9 mmol/L)


Other Outcome Measures:
  1. Quality of life: DTSQs questionnaire [ Time Frame: At week 4 , month 6 and month 12. ]

    Patients' quality of life will be assessed by participant-reported outcome measures (PROMS):

    the Diabetes Treatment Satisfaction Questionnaire - DTSQs


  2. Quality of life: DTSQc questionnaire [ Time Frame: At month 12 ]

    Patients' quality of life will be assessed by participant-reported outcome measures (PROMS):

    the Diabetes Treatment Satisfaction Questionnaire - DTSQc


  3. Quality of life: ADDQoL questionnaire [ Time Frame: At month 6 and at month 12 ]

    Patients' quality of life will be assessed by participant-reported outcome measures (PROMS):

    · the Audit of Diabetes Dependent Quality of Life - ADDQoL


  4. Quality of life: HypoFear questionnaire [ Time Frame: At week 4 , at month 6 and at month 12 ]
    Patients' quality of life will be assessed by participant-reported outcome measures (PROMS): the Hypoglycaemia Fear Survey - HFS



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have given written informed consent
  • Age ≥18 and <45 years at consent
  • Must have a diagnosis of T1D of within 6 weeks duration at screening (from date of the first insulin injection)
  • Must have at least one or more diabetes-related autoantibodies present at screening
  • Must have random C-peptide levels ≥200 pmol/L measured at screening
  • Be willing to comply with intensive diabetes management

Exclusion Criteria:

  • Be immunodeficient or have clinically significant chronic lymphopenia: Leukopenia (< 3,000 leukocytes /µL), neutropenia (<1,500 neutrophils/µL), lymphopenia (<800 lymphocytes/µL), or thrombocytopenia (<100,000 platelets/µL)
  • Have active signs or symptoms of acute infection at the time of screening
  • Be currently pregnant or lactating, or anticipate getting pregnant during the 12 months study period
  • Require use of immunosuppressive agents including chronic use of systemic steroids
  • Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection
  • Have any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, chronic obstructive pulmonary disease (COPD), sickle cell disease, neurological, or blood count abnormalities as judged by the investigator
  • Have a history of malignancies other than skin
  • Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 3 times the upper limits of normal
  • Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit of normal
  • Current or ongoing use of non-insulin pharmaceuticals that affect glycaemic control within prior 7 days of screening
  • Use of any other investigational drug in the previous 30 days and/or intent on using any investigational drug for the duration of the trial
  • Current use of verapamil or other calcium channel blockers
  • Known hypersensitivity to verapamil or to any of the excipients, use of beta-blockers in patients with poor ventricular function, concomitant ingestion of grapefruit juice, combination with ivabradine
  • Hypotension (of less than 90mmHg systolic), sick sinus syndrome (except in patients with a functioning artificial pacemaker); uncompensated heart failure; marked bradycardia (less than 50 beats/minute), Wolff-Parkinson-White syndrome, acute myocardial infarction complicated by bradycardia, marked hypotension or left ventricular failure
  • ECG second or third degree atrioventricular block
  • Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04545151


Contacts
Layout table for location contacts
Contact: Martina Brunner, MSc +43 316 385 ext 72841 martina.brunner@medunigraz.at
Contact: Camelia Kaufmann, BSc +43 316 385 ext 72834 camelia.kaufmann@medunigraz.at

Locations
Show Show 20 study locations
Sponsors and Collaborators
Medical University of Graz
Juvenile Diabetes Research Foundation
Investigators
Layout table for investigator information
Principal Investigator: Thomas Pieber, MD, Prof Medical University of Graz
Principal Investigator: Dayan Colin, MD, Prof Cardiff University
Publications:

Layout table for additonal information
Responsible Party: Medical University of Graz
ClinicalTrials.gov Identifier: NCT04545151    
Other Study ID Numbers: Ver-A-T1D
2020-000435-45 ( EudraCT Number )
First Posted: September 10, 2020    Key Record Dates
Last Update Posted: September 10, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Medical University of Graz:
INNODIA
Typ-1 Diabetes
Verapamil
Beta cell
C-peptide
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Verapamil
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents